#duane boise jamaica

[duaneboise]

New Strides in Federal Cannabis Regulations

The DEA has recently announced that they are rewriting Obama’s federal cannabis regulations by processing pending applications for access to cannabis research. In addition, companies that are looking to obtain DEA registration to grow cannabis for research are also closer to their end goal.

Attorney General William P. Barr said that he is “pleased that DEA is moving forward with its review of applications for those who seek to grow marijuana legally to support research.” This decision to allow more applications to come through occurs after many long years of delays. Dr. Sue Sisley with the Scottsdale Research Institute of Arizona was a huge reason why the need regulations are being put into place. Dr. Sisley expressed increasing frustration at the low quality of research being disseminated from the University of Mississippi and felt that the university had the monopoly on medical cannabis for research purposes.

The “DEA is making progress in the program to register additional marijuana growers for federally authorized research, and will work with other relevant federal agencies to expedite the necessary next steps,” said DEA Acting Administrator Uttam Dhillon. “We support additional research into marijuana and its components, and we believe registering more growers will result in researchers having access to a wider variety for study.”

Though there has been progress in the process of rewriting the regulations, very few applicants will qualify. Currently, there are 33 applicants, but several will be disqualified due to their current or previous involvement in the cannabis industry. According to the DEA, being state-compliant automatically disqualifies applicants from being federally compliant. In order to qualify, applicants must comply with strict guidelines and demonstrate a case for the public interest.

Current applicants include the University of Massachusetts and the Hawaii Agriculture Research Institute, who are applying for an extract license. The University of California Davis is looking to grow cannabis. The applicants are not limited to universities and research institutes: Duane Boise, CEO of MMJ Biopharma Cultivation, based in Florida, believes that he has a chance at obtaining a federal license to cultivate medical marijuana.

“We meet the public interest requirement evidenced by our filings with the FDA, in our development of a cannabis-based drug to treat Multiple Sclerosis and Huntington’s Disease,” says Boise. He and his company have applied for the DEA bulk manufacturing license with the intention of the continued development of an FDA-approved pharmaceutical. Part of Boise’s plan is to cultivate on federally-protected Native American sovereign lands. In this mutually beneficial arrangement, MMJ Biopharma will employ many members of the tribe. So far, the only viable opportunity for cultivating federally-approved cannabis has been through an association with a university, but Duane Boise’s strategy may prove to be effective.

The DEA is expected to release their amendments to the 2016 Obama policy statement within the next 30 days. Of the 33 registered applicants, several have already been disqualified. Whether the applicants are approved remains to be seen.

This post was originally published on DuaneBoise.info

[duaneboise]

Medical Marijuana Helping Patients with Rheumatoid Arthritis

What is Rheumatoid Arthritis (RA)?

This autoimmune disease causes the body’s immune system to attack the joints instead of attacking foreign substances such as bacteria and viruses. The tissue line in the joints thickens which results in swelling and pain around the joints and the inflammation can damage cartilage and bones if it goes unchecked. Rheumatoid arthritis sufferers will fell their joints become tender, warm, and swollen. They can oftentimes feel fatigued, have fevers, and even lose their appetites. Over time, patients with RA can lose mobility due to the loss of cartilage and bone. 

Treatment

The damage caused by this disease cannot be reversed. When caught early on, doctors will use aggressive treatments to control the rheumatoid arthritis symptoms and possibly stop the disease from progressing. The medication will reduce or stop the inflammation and then target remission. Doctors will use medications to ease the symptoms and focus on preventing future inflammation.

How Can Marijuana Help?

Though there are medications out there that help patients diagnosed with rheumatoid arthritis to recover and can alter the course of the disease, medical marijuana can act as a complementary medicine therapy for patients. Marijuana can be used as an anti-inflammatory and help patients with chronic pain. There is no much research around the effects of marijuana helping rheumatoid arthritis patients due to their other methods of treating them. But with marijuana become more widely accepted as a form of medical treatment or therapy, the research will need to be done. 

Approximately 1.5 million people in the United States are suffering from RA. More research is being done in the medical field involving the use of medical marijuana. Companies are searching for new uses and treatment options that involve medical marijuana. At the forefront, MMJ International Holdings is working to become FDA approved with their treatments of Multiple Sclerosis and Huntington’s Disease. 

“We meet the public interest requirement evidenced by our filings with the FDA, in our development of a cannabis-based drug to treat Multiple Sclerosis and Huntington’s Disease. We have applied for the DEA bulk manufacturing license to continue our development of an FDA-approved pharmaceutical,” says Duane Boise.

In the near future, MMJ could obtain a federal license to cultivate medical marijuana, opening up more possibilities to improve marijuana research. 

This article was originally published on DuaneBoise.info

[duaneboise]

Applications of Medical 3D Printing

3D Printing is a revolutionary technology, and since its introduction into the medical field, it has shown great potential. The market research firm Garner predicted in 2015 that medical 3D printing would become the pioneering field that would push additive manufacturing (AM) into the mainstream within five years. At its simplest, 3D printing works by depositing material layer by layer to build along a third axis. The possibilities seem limitless as technology continues to advance and scientists find new applications of 3D printing. In this blog, we are going to take a closer look at some of these applications.

3D-Printed Implants

Osseus Fusion Systems received its FDA clearance for its Aries family of 3D-printed lumbar implants back in 2018. The design features 80 percent porosity and a proprietary mesh lattice that reduces stiffness while increasing bone cell growth. One of the key reasons that 3D printing is being adopted for the creation of surgical implants is that it makes it easy to customize the implant to the patient. These customizations in curvature and size can result in better outcomes for the patient by fitting them better than a mass-produced part. Currently, orthopedic devices are among the most prevalent of the 3D-printed implants, though spinal, craniomaxillofacial, and knee implants are increasing in number.

Bioprinting

The ultimate goal of bioprinting is the ability to 3D print patient-specific transplant organs.  This could eliminate the need for waiting lists and donors, and more importantly, the chances of organ rejection. Unfortunately, the technology is not quite there yet, though it is advancing. Scientists have printed a sort of organ “scaffolding” on which stem cells can be deposited to populate and eventually create an organ. While the hope of fully functioning, vascular organs is still distant, it is commonplace to 3D print layers of simple tissue. For example, Poietis is one company that has created a laser-based method for 3D printing biological matter like skin cells and liver tissue.

Surgical Tools

In the first two applications that we mentioned, we covered medical interventions, but 3D printing is also aiding in the evolution of medical tools. Endocon, a German medical company, developed a printed device that facilitates the extraction of hip cups. The use of 3D printing has decreased production time, reduced the rejection rate from 30 percent down to 3 percent, and dropped the cost per blade by 40 to 45 percent. Meanwhile, in the United States, Johnson & Johnson has introduced personalization in surgical tools with the help of 3D printing. Previously surgeons entered the operating room with a series of different tool sizes, but now they can use a patient’s CT scan to produce anatomy-specific tools, thus reducing operation time while improving effectiveness.

Originally published on DuaneBoise.info

[duaneboise]

MMJ Biopharma Cultivation In Line for DEA License

Earlier this year, the Drug Enforcement Administration (DEA) announced its plans to revise former President Obama’s federal cannabis regulations, and in doing so would process applications for access to cannabis research. In order to obtain a federal license, applicants must adhere to very strict guidelines, including demonstrating a case for the public interest. One way to do this is to submit a filing to the FDA for the development of a pharmaceutical, and of the 33 applicants so far, only two have filed for clinical trials with the FDA.

Universities and Research institutes are the most likely candidates to obtain a federal growing license, yet Duane Boise, CEO of MMJ Biopharma Cultivation, of Florida, believes that he has a decent chance at getting a license to cultivate medical marijuana. “We meet the public interest requirement evidenced by our filings with the FDA, in our development of a cannabis-based drug to treat Multiple Sclerosis and Huntington’s Disease. We have applied for the DEA bulk manufacturing license to continue our development of an FDA-approved pharmaceutical,” said Boise.

Aside from meeting the public interest requirement, Boise has another strategy: he plans to cultivate the crop on federally-protected Native American sovereign lands. The arrangement is mutually beneficial, as MMJ Biopharma will end up employing many members of the tribe. The only approach so far that would be a viable opportunity to cultivate federally-approved cannabis would be the association with a university, but Duane Boise manages to circumvent this with his nascent approach.

Sara Brittany Somerset of Forbes Online was able to exclusively obtain the DEA’s application, a 21 page long, 92 questionnaire process. The more mundane questions pertain to logistics such as proposed air filtration systems and security protocol. With regard to the latter, it is fortunate that the Native American tribe has its own police force.

The DEA amendments to the 2016 Obama policy statement will supersede the current policy in place and govern applicants seeking to become registered. One of the key revisions of the policy includes moving away from a single grower system and registering additional growers. The Department of Justice has also been involved in the process to “ensure that the marijuana growers program is consistent with applicable laws and treaties.”

Originally published on DuaneBoise.info